. Author manuscript; available in PMC: 2010 Dec 1.

Published in final edited form as: Neurochem Int. 2009 Aug 3;55(8):775–782. doi: 10.1016/j.neuint.2009.07.010

TABLE 1.

Summary of Gene Expression Changes in PCP Treated Rats

GABAergic Markers			NMDA Receptor Subunits			Neuromodulators
Gene of Interest	P/S Ratio	p value	Gene of Interest	P/S Ratio	p value	Gene of Interest	P/S Ratio	p value

GABA_A-α6	1.55^***	0.0001	NR1	0.95	0.1324	GluR6	0.84^**	0.0014
GABA_A-β3	1.28^**	0.0024	NR2A	1.00	0.0952	KA2	1.39^***	<0.0001
GABA_A-δ	1.55^***	0.0002	NR2B	0.78^**	0.0049	mGluR2	1.37	0.0610
GAD₆₅	0.82^**	0.0023	NR2C	1.09	0.6822	mGluR3	0.94	0.3612
GAD₆₇	0.89^**	0.0060	NR2D	0.74^**	0.0076	nNOS	1.15	0.1862
GAT-1	0.83^*	0.0242

Decreases in mRNA levels of GAD₆₅ and GAD₆₇ are seen in the cerebellum of PCP treated rats versus saline controls as shown by PCP/Saline expression ratios. All other gene changes are involved in GABAergic transmission between Golgi cells and granule cells. Differences in expression determined by t test

p<0.05

^**

p<0.01

^***

p<0.0001

N= 10 animals per group.